ACCESS Newswire
19 Sep 2023, 17:14 GMT+10
LEXINGTON, MA / ACCESSWIRE / September 19, 2023 / Hyku Biosciences, Inc. (Hyku) today announced its launch with $56 million in seed financing to develop precision covalent medicines in oncology. Hyku is deploying an innovative chemoproteomics platform that selectively disarms disease-causing proteins by covalently targeting ligandable amino acids such as histidines, tyrosines or lysines. Hyku was incubated by RAVen, RA Capital Management's company creation engine, and is based on groundbreaking chemoproteomics research at the University of Virginia by its scientific founder, Dr. Ku-Lung (Ken) Hsu. Dr. Hsu is a recipient of The Mark Foundation's Emerging Leader Award and currently The Stephen F. and Fay Evans Martin Endowed Associate Professor of Chemistry at The University of Texas at Austin.
'Hyku was created with a singular focus to improve patient lives using the power of covalent medicines. Hyku's innovative and unique platform integrates chemoproteomics, proprietary chemistry and bespoke computational and machine-learning algorithms to target critically important amino acids such as histidines, tyrosines and lysines to expand the druggable proteome. We are proud to have a team of accomplished scientists led by our CSO, Mark Mulvihill, PhD, to achieve Hyku's vision.' said Milind Deshpande, Ph.D., Founder, Acting CEO of Hyku and Venture Partner at RA Capital Management.
'Recent progress in covalent medicine has focused largely on targeting cysteines - Hyku builds on that progress, but now targeting proteins and sites only accessible with non-cysteine covalent chemistry,' said Laura Tadvalkar, Ph.D., Managing Director at RA Capital Management and Hyku Board member. 'We are proud to see the progress Hyku has made since its inception.'
'We believe that precision covalent medicines provide a promising approach to address current and emerging challenges in oncology. Hyku's in-house chemoproteomics platform allows the team to make rapid progress across a range of pipeline programs - both internal and potentially with partners in the future. We look forward to working with the Hyku team and support their bold vision,' said Matthias Van Woensel, Ph.D., Partner at Droia Ventures and Hyku Board member.
About Hyku Biosciences
Hyku Biosciences is a biotechnology company, based in the greater Boston area, building the leading covalent medicines discovery platform to inhibit disease targets which are challenging to address with conventional approaches. Hyku's drug discovery engine is based on its proprietary platform technologies, which identifies histidine, tyrosine and lysine based binding pockets and enables rational drug design for therapeutic development. The platform pioneered by Hyku has the potential to fundamentally expand the scope of small molecule drug discovery, greatly increase druggability across many target classes, and bring significant therapeutic benefits to patients via novel medicines. For more information, visit http://www.hykubiosciences.com
Contact:
SOURCE: Hyku Biosciences, Inc.
Get a daily dose of Bristol Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Bristol Star.
More InformationPARIS, France: L'Oréal is making a fresh play in the booming premium haircare segment with a new acquisition. The French beauty conglomerate...
LONDON, UK - Lawmakers in the United Kingdom have voted overwhelmingly to proscribe the direct-action group Palestine Action as a terrorist...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
(New York) - China's government has erased Hong Kong's freedoms since imposing the draconian National Security Law on June 30, 2020,...
New Delhi [India], July 4 (ANI): Congress General Secretary Jairam Ramesh on Friday took a dig at Prime Minister Narendra Modi on his...
Jaipur (Rajasthan) [India], July 4 (ANI): Rajasthan Chief Minister Bhajanlal Sharma on Friday applauded Prime Minister Narendra Modi,...
WASHINGTON, D.C.: President Donald Trump will meet Israeli Prime Minister Benjamin Netanyahu at the White House on Monday. President...
GENEVA, Switzerland: A new United Nations report alleges that dozens of global corporations are profiting from and helping sustain...
LONDON, UK - Lawmakers in the United Kingdom have voted overwhelmingly to proscribe the direct-action group Palestine Action as a terrorist...
DHARAMSHALA, India: The Dalai Lama is set to address a significant three-day conference of Buddhist leaders this week, coinciding with...
WASHINGTON, D.C.: In a significant ruling last week, the U.S. Supreme Court upheld a Texas law requiring age verification for users...
ISTANBUL/PARIS/BRUSSELS: As searing temperatures blanket much of Europe, wildfires are erupting and evacuation orders are being issued...